AMD is the leading cause of irreversible blindness in the elderly and today there is no effective treatment for the atrophic form of the disease

Gyroscope Therapeutics Ltd is developing cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system

Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.